You are using an outdated browser. We suggest you update your browser for a better experience. Click here for update.
Close this notification.
Skip to main content Skip to search

 

332 Results
Document
Mar 2022
Regimen
Cancer Type:
Hematologic, 
Lymphoma - Non-Hodgkin's High Grade, 
Lymphoma - Non-Hodgkin's Intermediate Grade
Show More Show more tags
, Show Less Show fewer tags
Intent: Curative
Funding:
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma
ODB - General Benefit
    dexamethasone
New Drug Funding Program
    Rituximab (Biosimilar IV) and Rituximab SC - Retreatment - Aggressive Histology Lymphoma
Show More Show more tags
, Show Less Show fewer tags
Drugs Used:
dexamethasone,
riTUXimab,
gemcitabine,
CARBOplatin,
riTUXimab (subcut)
... Show more tags
, Collapse Show fewer tags
Quick Link(s):
Regimen Monograph
Jan 2024
Document
Jul 2022
Guidelines and Advice
Status: Current
ID: GL 2-33
Version: 2
Jun 2025
Statistical Reports
Document
Nov 2022
Document
Nov 2022
Document
Dec 2022
Document
Dec 2022
.
Find information and best practice resources for health care providers about the types of genetic testing available and where they are offered.
Les fournisseurs de soins de santé trouveront ici des renseignements et des ressources de pratiques exemplaires au sujet des types de dépistage...

Pages